Mahmoud Ghannam

Title: Mahmoud Ghannam: Innovator in Oral Dosage Forms

Introduction

Mahmoud Ghannam is a notable inventor based in Amman, Jordan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of oral dosage forms for cancer treatment.

Latest Patents

Ghannam holds a patent for "Oral dosage forms of ibrutinib." This patent describes stable and bioavailable oral dosage forms of ibrutinib, which include an acidifying agent. The formulations may also contain a binder, such as sodium alginate, a surfactant, a lubricant, a filler, and/or a disintegrant. The methods outlined in the patent focus on treating cancers, especially blood cancers, and graft versus host disease by administering these dosage forms to patients in need.

Career Highlights

He is currently associated with Hikma Pharmaceuticals USA Inc., where he continues to innovate in the pharmaceutical sector. His work is pivotal in enhancing the effectiveness of cancer treatments through improved drug formulations.

Collaborations

Some of his notable coworkers include Shahin Fesharaki and Mohammad Al Hreebat, who contribute to the collaborative efforts in research and development within the company.

Conclusion

Mahmoud Ghannam's work in developing oral dosage forms of ibrutinib showcases his commitment to advancing cancer treatment options. His innovative approach and collaboration with colleagues highlight the importance of teamwork in the field of pharmaceuticals.